In locally advanced breast cancer, P53 mutated non-inflammatory carcinomas had a high rate of complete pathological response to dose-dense doxorubicin-cyclophosphamide chemotherapy, while p53 wild-type tumors never achieved complete response [17]. This evidence concerns the gene TP53 and breast cancer.